Frederic Troalen
Overview
Explore the profile of Frederic Troalen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perrier A, Hainaut P, Guenoun A, Nguyen D, Lamy P, Guerber F, et al.
Bull Cancer
. 2022 Jan;
109(2):170-184.
PMID: 35034786
Technological advances, in particular the development of high-throughput sequencing, have led to the emergence of a new generation of molecular biomarkers for tumors. These new tools have profoundly changed therapeutic...
2.
Perrier A, Hainaut P, Lamy P, Guenoun A, Nguyen D, Guerber F, et al.
Bull Cancer
. 2022 Jan;
109(2):151-169.
PMID: 35012767
In oncology, the identification of targets that correlate with a type of cancer has led to a profound change in the notion of "tumor markers". Technological advances, in particular the...
3.
Hajem S, Ederhy S, Champiat S, Troalen F, Nolin-Lapalme A, Berhoune M, et al.
Eur J Cancer
. 2021 Sep;
157:383-390.
PMID: 34571335
Aim: Despite unprecedented results of anti-programmed death protein (ligand) 1 (PD-(L)1) immune checkpoint inhibitor in the oncology's armamentarium, immune-related adverse events (irAEs) represent a therapeutic hurdle. Currently, there is no...
4.
Dekaliuk M, Qiu X, Troalen F, Busson P, Hildebrandt N
ACS Sens
. 2019 Oct;
4(10):2786-2793.
PMID: 31577130
The quantification of very low concentrations of circulating tumor DNA (ctDNA) biomarkers from liquid biopsies has become an important requirement for clinical diagnostics and personalized medicine. In particular, the simultaneous...
5.
Vazeille C, Massard C, Loriot Y, Albiges L, Troalen F, Escudier B, et al.
Clin Genitourin Cancer
. 2015 Oct;
14(1):e91-3.
PMID: 26422013
No abstract available.
6.
Deandreis D, Terroir M, Al Ghuzlan A, Berdelou A, Lacroix L, Bidault F, et al.
Eur J Nucl Med Mol Imaging
. 2015 Aug;
42(12):1941-2.
PMID: 26253272
No abstract available.
7.
Saada S, Olichet B, Bronzini T, Berrafato S, Lokiec F, Rezai K, et al.
Ann Biol Clin (Paris)
. 2012 May;
70(3):277-86.
PMID: 22565175
High-dose methotrexate treatment requires pharmacological monitoring in order to tailor administration of folinic acid to reduce side effects. The aim of the study was to validate the adaptation of the...
8.
Even C, Lhomme C, Duvillard P, Morice P, Balleyguier C, Pautier P, et al.
Bull Cancer
. 2011 Jun;
98(8):963-75.
PMID: 21708513
Ovarian yolk sac tumour (OYST) is a very rare malignancy arising most often in young women. Preoperative clinical, biological (alpha-foetoprotein) and radiological findings should help to establish the diagnosis of...
9.
de La Motte Rouge T, Pautier P, Rey A, Duvillard P, Kerbrat P, Troalen F, et al.
Eur J Cancer
. 2010 Sep;
47(2):175-82.
PMID: 20851596
Background: Ovarian yolk sac tumour (OYST) is a very rare malignancy arising in young women. Our study aimed to evaluate long-term outcomes and to identify prognostic parameters likely to help...
10.
Semeraro M, Thomee C, Rolland E, Cecile Le Deley M, Rosselini D, Troalen F, et al.
Pediatr Blood Cancer
. 2009 Nov;
54(2):284-90.
PMID: 19927283
Background: No sensitive, specific marker able to discriminate favourable or unfavourable outcome of fever of unknown origin (FUO) at diagnosis has been identified. Procalcitonin, a recently assessed infection marker, may...